Placental mesenchymal stromal cells rescue ambulation in ovine myelomeningocele

Aijun Wang, Erin Brown, Lee Lankford, Benjamin A. Keller, Christopher D. Pivetti, Nicole A. Sitkin, Michael S. Beattie, Jacqueline C. Bresnahan, Diana L Farmer

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Myelomeningocele (MMC)—commonly known as spina bifida—is a congenital birth defect that causes lifelong paralysis, incontinence, musculoskeletal deformities, and severe cognitive disabilities. The recent landmark Management of Myelomeningocele Study (MOMS) demonstrated for the first time in humans that in utero surgical repair of the MMC defect improves lower limb motor function, suggesting a capacity for improved neurologic outcomes in this disorder. However, functional recovery was incomplete, and 58% of the treated children were unable to walk independently at 30 months of age. In the present study, we demonstrate that using early gestation human placenta-derived mesenchymal stromal cells (PMSCs) to augment in utero repair of MMC results in significant and consistent improvement in neurologic function at birth in the rigorous fetal ovine model of MMC. In vitro, human PMSCs express characteristic MSC markers and trilineage differentiation potential. Protein array assays and enzyme-linked immunosorbent assay show that PMSCs secrete a variety of immunomodulatory and angiogenic cytokines. Compared with adult bone marrow MSCs, PMSCs secrete significantly higher levels of brain-derived neurotrophic factor and hepatocyte growth factor, both of which have known neuroprotective capabilities. In vivo, functional and histopathologic analysis demonstrated that human PMSCs mediate a significant, clinically relevant improvement in motor function in MMC lambs and increase the preservation of large neurons with in the spinal cord. These preclinical results in the well-established fetal ovine model of MMC provide promising early support for translating in utero stem cell therapy for MMC into clinical application for patients.

Original languageEnglish (US)
Pages (from-to)659-669
Number of pages11
JournalStem cells translational medicine
Volume4
Issue number6
DOIs
StatePublished - 2015

Fingerprint

Meningomyelocele
Mesenchymal Stromal Cells
Walking
Sheep
Placenta
Nervous System
Protein Array Analysis
Hepatocyte Growth Factor
Brain-Derived Neurotrophic Factor
Differentiation Antigens
Cell- and Tissue-Based Therapy
Paralysis
Lower Extremity
Spinal Cord
Stem Cells
Bone Marrow
Enzyme-Linked Immunosorbent Assay
Parturition
Cytokines
Neurons

Keywords

  • Cellular therapy
  • Fetal stem cells
  • Mesenchymal stem cells
  • Placenta
  • Stem cell

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology

Cite this

Placental mesenchymal stromal cells rescue ambulation in ovine myelomeningocele. / Wang, Aijun; Brown, Erin; Lankford, Lee; Keller, Benjamin A.; Pivetti, Christopher D.; Sitkin, Nicole A.; Beattie, Michael S.; Bresnahan, Jacqueline C.; Farmer, Diana L.

In: Stem cells translational medicine, Vol. 4, No. 6, 2015, p. 659-669.

Research output: Contribution to journalArticle

Wang, Aijun ; Brown, Erin ; Lankford, Lee ; Keller, Benjamin A. ; Pivetti, Christopher D. ; Sitkin, Nicole A. ; Beattie, Michael S. ; Bresnahan, Jacqueline C. ; Farmer, Diana L. / Placental mesenchymal stromal cells rescue ambulation in ovine myelomeningocele. In: Stem cells translational medicine. 2015 ; Vol. 4, No. 6. pp. 659-669.
@article{bc9064909b994e209e558039311aef9b,
title = "Placental mesenchymal stromal cells rescue ambulation in ovine myelomeningocele",
abstract = "Myelomeningocele (MMC)—commonly known as spina bifida—is a congenital birth defect that causes lifelong paralysis, incontinence, musculoskeletal deformities, and severe cognitive disabilities. The recent landmark Management of Myelomeningocele Study (MOMS) demonstrated for the first time in humans that in utero surgical repair of the MMC defect improves lower limb motor function, suggesting a capacity for improved neurologic outcomes in this disorder. However, functional recovery was incomplete, and 58{\%} of the treated children were unable to walk independently at 30 months of age. In the present study, we demonstrate that using early gestation human placenta-derived mesenchymal stromal cells (PMSCs) to augment in utero repair of MMC results in significant and consistent improvement in neurologic function at birth in the rigorous fetal ovine model of MMC. In vitro, human PMSCs express characteristic MSC markers and trilineage differentiation potential. Protein array assays and enzyme-linked immunosorbent assay show that PMSCs secrete a variety of immunomodulatory and angiogenic cytokines. Compared with adult bone marrow MSCs, PMSCs secrete significantly higher levels of brain-derived neurotrophic factor and hepatocyte growth factor, both of which have known neuroprotective capabilities. In vivo, functional and histopathologic analysis demonstrated that human PMSCs mediate a significant, clinically relevant improvement in motor function in MMC lambs and increase the preservation of large neurons with in the spinal cord. These preclinical results in the well-established fetal ovine model of MMC provide promising early support for translating in utero stem cell therapy for MMC into clinical application for patients.",
keywords = "Cellular therapy, Fetal stem cells, Mesenchymal stem cells, Placenta, Stem cell",
author = "Aijun Wang and Erin Brown and Lee Lankford and Keller, {Benjamin A.} and Pivetti, {Christopher D.} and Sitkin, {Nicole A.} and Beattie, {Michael S.} and Bresnahan, {Jacqueline C.} and Farmer, {Diana L}",
year = "2015",
doi = "10.5966/sctm.2014-0296",
language = "English (US)",
volume = "4",
pages = "659--669",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "6",

}

TY - JOUR

T1 - Placental mesenchymal stromal cells rescue ambulation in ovine myelomeningocele

AU - Wang, Aijun

AU - Brown, Erin

AU - Lankford, Lee

AU - Keller, Benjamin A.

AU - Pivetti, Christopher D.

AU - Sitkin, Nicole A.

AU - Beattie, Michael S.

AU - Bresnahan, Jacqueline C.

AU - Farmer, Diana L

PY - 2015

Y1 - 2015

N2 - Myelomeningocele (MMC)—commonly known as spina bifida—is a congenital birth defect that causes lifelong paralysis, incontinence, musculoskeletal deformities, and severe cognitive disabilities. The recent landmark Management of Myelomeningocele Study (MOMS) demonstrated for the first time in humans that in utero surgical repair of the MMC defect improves lower limb motor function, suggesting a capacity for improved neurologic outcomes in this disorder. However, functional recovery was incomplete, and 58% of the treated children were unable to walk independently at 30 months of age. In the present study, we demonstrate that using early gestation human placenta-derived mesenchymal stromal cells (PMSCs) to augment in utero repair of MMC results in significant and consistent improvement in neurologic function at birth in the rigorous fetal ovine model of MMC. In vitro, human PMSCs express characteristic MSC markers and trilineage differentiation potential. Protein array assays and enzyme-linked immunosorbent assay show that PMSCs secrete a variety of immunomodulatory and angiogenic cytokines. Compared with adult bone marrow MSCs, PMSCs secrete significantly higher levels of brain-derived neurotrophic factor and hepatocyte growth factor, both of which have known neuroprotective capabilities. In vivo, functional and histopathologic analysis demonstrated that human PMSCs mediate a significant, clinically relevant improvement in motor function in MMC lambs and increase the preservation of large neurons with in the spinal cord. These preclinical results in the well-established fetal ovine model of MMC provide promising early support for translating in utero stem cell therapy for MMC into clinical application for patients.

AB - Myelomeningocele (MMC)—commonly known as spina bifida—is a congenital birth defect that causes lifelong paralysis, incontinence, musculoskeletal deformities, and severe cognitive disabilities. The recent landmark Management of Myelomeningocele Study (MOMS) demonstrated for the first time in humans that in utero surgical repair of the MMC defect improves lower limb motor function, suggesting a capacity for improved neurologic outcomes in this disorder. However, functional recovery was incomplete, and 58% of the treated children were unable to walk independently at 30 months of age. In the present study, we demonstrate that using early gestation human placenta-derived mesenchymal stromal cells (PMSCs) to augment in utero repair of MMC results in significant and consistent improvement in neurologic function at birth in the rigorous fetal ovine model of MMC. In vitro, human PMSCs express characteristic MSC markers and trilineage differentiation potential. Protein array assays and enzyme-linked immunosorbent assay show that PMSCs secrete a variety of immunomodulatory and angiogenic cytokines. Compared with adult bone marrow MSCs, PMSCs secrete significantly higher levels of brain-derived neurotrophic factor and hepatocyte growth factor, both of which have known neuroprotective capabilities. In vivo, functional and histopathologic analysis demonstrated that human PMSCs mediate a significant, clinically relevant improvement in motor function in MMC lambs and increase the preservation of large neurons with in the spinal cord. These preclinical results in the well-established fetal ovine model of MMC provide promising early support for translating in utero stem cell therapy for MMC into clinical application for patients.

KW - Cellular therapy

KW - Fetal stem cells

KW - Mesenchymal stem cells

KW - Placenta

KW - Stem cell

UR - http://www.scopus.com/inward/record.url?scp=84930518543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930518543&partnerID=8YFLogxK

U2 - 10.5966/sctm.2014-0296

DO - 10.5966/sctm.2014-0296

M3 - Article

C2 - 25911465

AN - SCOPUS:84930518543

VL - 4

SP - 659

EP - 669

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 6

ER -